Before #JPM20 kicked off this week, I spoke with Aligos Therapeutics CEO Blatt about the company's $125M series B and its three different approaches to treat #HBV

Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: biocentury.com/article/304364. Meanwhile, at least 9 trials of #2019-nCoV therapies are underway. biocentury.com/article/304364 All BioCentury coverage of the outbreak is in front of the paywall at biocentury.com/coronavirus.

.Gilead Sciences CEO O’Day says patients will be focus of its #2019nCoV response, not patents

Please donate if you can! UC San Francisco needs supplies to combat #COVID19 #coronavirus

Why steve usdin says FDA's authorization of malaria drugs to treat #COVID19 was unwise. buff.ly/2JGgIlv

The BioCentury team is dedicated to covering the #COVID19 pandemic: The science of #SARSCoV2, therapeutic and vaccine development, policies coming out of Washington, and more. Check out our free content here: biocentury.com/coronavirus

A pair of deals this week (Vir Biotechnology+GenerationBio and Neurimmune+Ethris) are centered on emerging tech that could accelerate development of a #COVID19 therapy by turning a patient's body into an antibody manufacturer biocentury.com/article/304812

FDA green-lights more than 70 #COVID19 trials via treatment acceleration program - Elizabeth S. Eaton via BioCentury $BSGM #PharmaIndustry #MedicalResearch #Healthcare biocentury.com/article/304954

BREAKING: Dr. Janet Woodcock stepping away as U.S. FDA CDER director to focus on #COVID19, Marks leaving Operation Warp Speed to focus on response w/in CBER. steve usdin via BioCentury biocentury.com/article/305254

As $ABBV continues to aggressively pursue ways to offset future generic competition for its top seller, Humira, the company's latest deal marks something of a course correction toward innovation after its $AGN takeout. via Elizabeth S. Eaton in BioCentury biocentury.com/article/305424

.sandi wong explores neutralization data for Moderna's #COVID19 #vaccine -- the highest titers reported to date

🚨🚨Here’s the big piece I’ve been promising: an Atlantic cover story about the US’s catastrophic mishandling of the pandemic. It’s a full autopsy of what went wrong, every unattended weakness & unheeded warning, every festering wound & reopened scar. 1/ theatlantic.com/magazine/archi…

Follow @Boost_Infinite for direct access to Boost Infinite launch updates

What a fitting end to the GA launch week, thanks to Nasdaq DevRev

Exceptionally excited to share this paper from D2G Oncology. Big thanks to Ian Winters Dmitri Petrov @labwinslow and the rest of the team at D2G. It’s been a really fun collaboration, thanks to @politikaterina Dow Lab @cellecta biorxiv.org/content/10.110… 1/n

Truly seminal piece of work - in both implications on our understanding of cancer biology and the interdisciplinary methods by which we can interrogate it. Great job D2G Oncology team on advancing this work! #oncology #biotech

The public launch of DevRev’s #DevCRM platform offers a new approach to managing SaaS customer management. More insight from co-founders Dheeraj Pandey and Manoj Agarwal in #CRMBuyer. crmbuyer.com/story/devrev-b…